oth operating units Novo Nordisk ® Reported therapy area sales and growth for first quarter of 2023 DKK billion North America Operations Growth at CER International Operations 60 25% 50% -11% 124% -16% 40 10% 20 41% 52% 50% IO -8% NAO -18% IO 65% NAO 156% IO NAO -17% -14% 0 Total 1 GLP-1 Insulin Obesity care Rare disease World; NAO: North America Operations; CER: Constant exchange rates
Download PDF file